"[Part D] is a fiercely competitive market

... where the plans are really pushed to try to bring the most value to consumers, [but] plans also have to feel that their benefit design is no more generous than others in the market because they will fear selection. So they will not want to be the plan that is the most generous for oral oncolytics or for [multiple sclerosis] because they don't want to attract those patients because that will make it more difficult for them to bid. There's always a drive to get more cost-effective medication and a need to accommodate technology, and so it's always a mix."

— Dan Mendelson, CEO of Avalere Health LLC, told AIS's Drug Benefit News.